PI
MRTX

PEAK6 Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PEAK6 Investments’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$5.88K – 4930
2023
Q4 		$5.88K Buy
+100
New +$5.62K ﹤0.01% 3964
2023
Q3 		– Sell
-2,100
Closed -$75.9K – 4709
2023
Q2 		$75.9K Buy
+2,100
New +$86.5K ﹤0.01% 3327
2022
Q3 		– Sell
-2,100
Closed -$75.9K – 6388
2022
Q2 		$75.9K Sell
2,100
-24,100
-92% -$1.53M ﹤0.01% 5373
2022
Q1 		$2.15M Buy
+26,200
New +$2.68M ﹤0.01% 1778

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PEAK6 Investments's MRTX Position: Q1 2024 in Review

PEAK6 Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,003 shares — an estimated $1.18M sold.

PEAK6 Investments first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $2.2M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • PEAK6 Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • PEAK6 Investments sold 20,003 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.18M.
  • PEAK6 Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
  • PEAK6 Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $2.2M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.